Abstract: Received: 10 May 2021 Revised: 29 September 2021 Accepted: 12 October 2021 DOI: 10.1002/ptr.7319 RESEARCH ARTICLE Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial Guitti Pourdowlat1 | Fatemeh Saghafi2 | Abolfazl Mozafari3 | Adeleh Sahebnasagh4 | Atefeh Abedini1 | Mohsen Nabi Meybodi5 | Ali Salehi Nezamabadi6 | Seyed Ruhollah Mousavinasab7 | Arda Kiani8 9 10 | | Mehdi Gholmzadeh Baeis | Esmaeil Eidani12 | Hanieh Raji | Nadia Soltani Abdolrahim Sadeghi Yakhdani13 | Fatemeh Movaseghi3 | Solomon Habtemariam14 | Zohreh Akhoundi Meybodi15 | 11 Mohsen Gholinataj Jelodar16 1 Chronic Respiratory Diseases Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran 2 Department of Clinical Pharmacy, School of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 3 Department of Medical Sciences, Qom Branch, Islamic Azad University, Qom, Iran 4 Clinical Research Center, Department of Internal Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran 5 Department of Pharmaceutics, School of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran 6 Department of Cardiology, Tehranpars Hospital, Tehran, Iran 7 Infectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 8 Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran 9 Department of Internal Medicine, Air pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 10 Pharmaceutical Sciences Research Center, School of Pharmacy, Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 11 Department of Radiology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran 12 NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran 13 Department of Radiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 14 Pharmacognosy Research Laboratories and Herbal Analysis Services UK, University of Greenwich, Kent, UK 15 Infectious Disease Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran 16 Department of Internal Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran Correspondence Mohsen Gholinataj Jelodar, Department of Internal Medicine, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Email: dr.natajm@gmail.com Abstract Colchicine has shown clinical benefits in the management of COVID-19 via its antiinflammatory effect. However, the exact role of colchicine in COVID-19 patients is unknown. The current clinical trial was performed on 202 patients with moderate to severe COVID-19. Patients were randomly assigned in a 1:1 ratio to receive up to a 3-day course of 0.5 mg colchicine followed by a 12-day course of 1 mg colchicine in combination with standard care or a 15-day course of standard care. Among 202 randomized patients, 153 completed the study and received colchicine/standard care or List of Abbreviations:..